Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer

Breast Cancer Research

Volumn 13, Issue 5, 2011, Pages

  Furth, Priscilla A ^a,b,c   Nakles, Rebecca E ^a   Millman, Sarah ^a   Diaz Cruz, Edgar S ^a   Cabrera, M Carla ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTEGRIN; CAVEOLIN; CYCLIN D1; DYSTROGLYCAN; ERYTHROPOIETIN; GROWTH HORMONE; HEAT SHOCK PROTEIN 90; JANUS KINASE 2; NAVELBINE; OSTEOCLAST DIFFERENTIATION FACTOR; PACLITAXEL; PROGESTERONE; PROGESTERONE RECEPTOR; PROLACTIN; PROTEIN BCL 6; PROTEIN KINASE B; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSFORMING GROWTH FACTOR BETA;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST CELL; BREAST EPITHELIUM; CANCER GROWTH; CANCER MODEL; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DEVELOPMENTAL BIOLOGY; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GONAD DEVELOPMENT; HUMAN; MAMMARY GLAND; NONHUMAN; ONCOGENE SRC; PROGNOSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; UPREGULATION; ANIMAL; BREAST TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PATHOLOGY; UDDER;

ANIMALS; BREAST NEOPLASMS; EPITHELIAL CELLS; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; STEM CELLS;

EID: 80054114850     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2921     Document Type: Review

References (99)

1. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008, 22:711-721. 10.1101/gad.1643908, 2394721,2394721, 18347089.
2. Desrivieres S, Kunz C, Barash I, Vafaizadeh V, Borghouts C, Groner B. The Biological Functions of the Versatile Transcription Factors STAT3 and STAT5 and New Strategies for their Targeted Inhibition. J Mammary Gland Biol Neoplasia 2006, 11:75-87. 10.1007/s10911-006-9014-4, 16947086.
3. Ferbeyre G, Moriggl R. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta 2011, 1815:104-114.
4. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23:8017-8023. 10.1038/sj.onc.1208159, 15489919.
5. Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 1995, 92:8831-8835. 10.1073/pnas.92.19.8831, 41061, 7568026.
6. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997, 11:179-186. 10.1101/gad.11.2.179, 9009201.
7. Hennighausen L, Robinson GW, Wagner KU, Liu X. Developing a mammary gland is a stat affair. J Mammary Gland Biol Neoplasia 1997, 2:365-372. 10.1023/A:1026347313096, 10935024.
8. Li M, Liu X, Robinson G, Bar-Peled U, Wagner KU, Young WS, Hennighausen L, Furth PA. Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA 1997, 94:3425-3430. 10.1073/pnas.94.7.3425, 20386, 9096410.
9. Liu X, Gallego MI, Smith GH, Robinson GW, Hennighausen L. Functional rescue of Stat5a-null mammary tissue through the activation of compensating signals including Stat5b. Cell Growth Differ 1998, 9:795-803.
10. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 1997, 94:7239-7244. 10.1073/pnas.94.14.7239, 23803, 9207075.
11. Pontillo C, Garcia M, Pena D, Cocca C, Chiappini F, Alvarez L, Kleiman de Pisarev D, Randi A. Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDAMB-231 human breast cancer cell line. Toxicol Sci 2011, 120:284-296. 10.1093/toxsci/kfq390, 21205633.
12. Lim E-J, Joung Y-H, Jung S-M, Park SH, Park JH, Kim SY, Hwang TS, Hong DY, Chung SC, Ye S-K, Moon E-S, Park EU, Park T, Chung I-M, Yang YM. Hemin inhibits cyclin D1 and IGF-1 expression via STAT5b under hypoxia in ERalpha-negative MDA-MB 231 breast cancer cells. Int J Oncol 2010, 36:1243-1251.
13. Tang J-Z, Zuo Z-H, Kong X-J, Steiner M, Yin Z, Perry JK, Zhu T, Liu D-X, Lobie PE. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology 2010, 151:43-55. 10.1210/en.2009-0651, 19966185.
14. Bernaciak TM, Zareno J, Parsons JT, Silva CM. A novel role for signal transducer and activator of transcription 5b (STAT5b) in beta1-integrinmediated human breast cancer cell migration. Breast Cancer Res 2009, 11:R52. 10.1186/bcr2341, 2750113, 19630967.
15. Joung Y-H, Lim E-J, Kim M-S, Lim SD, Yoon S-Y, Lim YC, Yoo YB, Ye S-K, Park T, Chung I-M, Bae K-Y, Yang YM. Enhancement of hypoxia-induced apoptosis of human breast cancer cells via STAT5b by momilactone B. Int J Oncol 2008, 33:477-484.
16. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol 2008, 22:1781-1796. 10.1210/me.2007-0419, 2505329, 18550772.
17. Tan SH, Nevalainen MT. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 2008, 15:367-390. 10.1677/ERC-08-0013, 18508994.
18. Wang R-A, Vadlamudi RK, Bagheri-Yarmand R, Beuvink I, Hynes NE, Kumar R. Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J Cell Biol 2003, 161:583-592. 10.1083/jcb.200212066, 2172951, 12732616.
19. Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am J Pathol 2010, 177:2971-2983. 10.2353/ajpath.2010.090399, 20952588.
20. Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008, 13:93-103. 10.1007/s10911-008-9062-z, 18228120.
21. Yamaji D, Na R, Feuermann Y, Pechhold S, Chen W, Robinson GW, Hennighausen L. Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev 2009, 23:2382-2387. 10.1101/gad.1840109, 2764497, 19833766.
22. Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J Endocrinol 2010, 206:1-11. 10.1677/JOE-10-0069, 20371569.
23. Arendt LM, Evans LC, Rugowski DE, Garcia-Barchino MJ, Rui H, Schuler LA. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. J Endocrinol 2009, 203:99-110. 10.1677/JOE-09-0221, 2841967, 19635758.
24. Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res 2011, 13:R11. 10.1186/bcr2819, 3109579, 21276249.
25. Kelly PA, Bachelot A, Kedzia C, Hennighausen L, Ormandy CJ, Kopchick JJ, Binart N. The role of prolactin and growth hormone in mammary gland development. Mol Cell Endocrinol 2002, 197:127-131. 10.1016/S0303-7207(02)00286-1, 12431805.
26. Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner K-U, Kirken RA, Rui H. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol 2007, 21:2218-2232. 10.1210/me.2007-0173, 17550976.
27. Watkin H, Richert MM, Lewis A, Terrell K, McManaman JP, Anderson SM. Lactation failure in Src knockout mice is due to impaired secretory activation. BMC Dev Biol 2008, 8:6. 10.1186/1471-213X-8-6, 2266720, 18215306.
28. Fox EM, Andrade J, Shupnik MA. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 2009, 74:622-627. 10.1016/j.steroids.2008.10.014, 2702758, 18996136.
29. Garcia-Martinez JM, Calcabrini A, Gonzalez L, Martin-Forero E, Agullo-Ortuno MT, Simon V, Watkin H, Anderson SM, Roche S, Martin-Perez J. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. Cell Signal 2010, 22:415-426. 10.1016/j.cellsig.2009.10.013, 19892015.
30. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang C-Y, Li Y, Li X, Chen C-T, Mills GB, Hortobagyi GN, Mendelsohn J, Hung M-C, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010, 18:423-435. 10.1016/j.ccr.2010.10.025, 21075308.
31. Groner B, Hynes NE. Unfavorable drug interactions in targeted breast cancer therapy. Cancer Cell 2010, 18:401-402. 10.1016/j.ccr.2010.10.027, 21075302.
32. Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, Kopchick JJ, Oka T, Kelly PA, Hennighausen L. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol 2001, 229:163-175. 10.1006/dbio.2000.9961, 11133161.
33. Tvorogov D, Sundvall M, Kurppa K, Hollmen M, Repo S, Johnson MS, Elenius K. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem 2009, 284:5582-5591.
34. Yang S, Raymond-Stintz MA, Ying W, Zhang J, Lidke DS, Steinberg SL, Williams L, Oliver JM, Wilson BS. Mapping ErbB receptors on breast cancer cell membranes during signal transduction. J Cell Sci 2007, 120:2763-2773. 10.1242/jcs.007658, 17652160.
35. Jones FE, Welte T, Fu XY, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 1999, 147:77-88. 10.1083/jcb.147.1.77, 2164978, 10508857.
36. Himpe E, Kooijman R. Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway. Biofactors 2009, 35:76-81. 10.1002/biof.20, 19319849.
37. Wood CE, Register TC, Cline JM. Transcriptional profiles of progestogen effects in the postmenopausal breast. Breast Cancer Res Treat 2009, 114:233-242. 10.1007/s10549-008-0003-8, 18404370.
38. Lange CA, Richer JK, Shen T, Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 1998, 273:31308-31316. 10.1074/jbc.273.47.31308, 9813039.
39. Santos SJ, Haslam SZ, Conrad SE. Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland. Endocrinology 2008, 149:329-338. 2194608, 17884938.
40. Petersen H, Haldosen LA. EGF modulates expression of STAT5 in mammary epithelial cells. Exp Cell Res 1998, 243:347-358. 10.1006/excr.1998.4160, 9743594.
41. Menzies KK, Lee HJ, Lefevre C, Ormandy CJ, Macmillan KL, Nicholas KR. Insulin, a key regulator of hormone responsive milk protein synthesis during lactogenesis in murine mammary explants. Funct Integr Genomics 2010, 10:87-95. 10.1007/s10142-009-0140-0, 19830464.
42. Choi YS, Chakrabarti R, Escamilla-Hernandez R, Sinha S. Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol 2009, 329:227-241. 10.1016/j.ydbio.2009.02.032, 19269284.
43. Miermont AM, Parrish AR, Furth PA. Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis. Carcinogenesis 2010, 31:1124-1131. 10.1093/carcin/bgq048, 2878361, 20181624.
44. Boerner JL, Gibson MA, Fox EM, Posner ED, Parsons SJ, Silva CM, Shupnik MA. Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. Mol Endocrinol 2005, 19:2660-2670. 10.1210/me.2004-0439, 15976008.
45. Bjornstrom L, Kilic E, Norman M, Parker MG, Sjoberg M. Cross-talk between Stat5b and estrogen receptor-alpha and -beta in mammary epithelial cells. J Mol Endocrinol 2001, 27:93-106. 10.1677/jme.0.0270093, 11463580.
46. Buser AC, Gass-Handel EK, Wyszomierski SL, Doppler W, Leonhardt SA, Schaack J, Rosen JM, Watkin H, Anderson SM, Edwards DP. Progesterone receptor repression of prolactin/signal transducer and activator of transcription 5-mediated transcription of the beta-casein gene in mammary epithelial cells. Mol Endocrinol 2007, 21:106-125.
47. Bertucci PY, Quaglino A, Pozzi AG, Kordon EC, Pecci A. Glucocorticoidinduced impairment of mammary gland involution is associated with STAT5 and STAT3 signaling modulation. Endocrinology 2010, 151:5730-5740. 10.1210/en.2010-0517, 20881248.
48. Rocha-Viegas L, Vicent GP, Barañao JL, Beato M, Pecci A. Glucocorticoids repress bcl-X expression in lymphoid cells by recruiting STAT5B to the P4 promoter. J Biol Chem 2006, 281:33959-33970. 10.1074/jbc.M602408200, 16959781.
49. Litterst CM, Kliem S, Marilley D, Pfitzner E. NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain. J Biol Chem 2003, 278:45340-45351. 10.1074/jbc.M303644200, 12954634.
50. Cella N, Groner B, Hynes NE. Characterization of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocortiocoid receptor in mammary cells. Mol Cell Biol 1998, 18:1783-1792. 121408, 9528750.
51. Chan C-B, Liu X, Ensslin MA, Dillehay DL, Ormandy CJ, Sohn P, Serra R, Ye K. PIKE-A is required for prolactin-mediated STAT5a activation in mammary gland development. EMBO J 2010, 29:956-968. 10.1038/emboj.2009.406, 2837170, 20075866.
52. Chen CC, Boxer RB, Stairs DB, Portocarrero CP, Horton RH, Alvarez JV, Birnbaum MJ, Chodosh LA. Akt is required for Stat5 activation and mammary differentiation. Breast Cancer Res 2010, 12:R72. 10.1186/bcr2640, 3096959, 20849614.
53. Fang F, Rycyzyn MA, Clevenger CV. Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. Endocrinology 2009, 150:1597-1606. 10.1210/en.2008-1079, 2659289, 19036881.
54. Ikeda O, Mizushima A, Sekine Y, Yamamoto C, Muromoto R, Nanbo A, Oritani K, Yoshimura A, Matsuda T. Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells. Cancer Sci 2011, 102:756-761. 10.1111/j.1349-7006.2010.01842.x, 21205088.
55. Sotgia F, Williams TM, Schubert W, Medina F, Minetti C, Pestell RG, Lisanti MP. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol 2006, 168:292-309. 10.2353/ajpath.2006.050429, 1592656, 16400031.
56. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR. STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology 2001, 142:3836-3841. 10.1210/en.142.9.3836, 11517160.
57. Haffner MC, Petridou B, Peyrat JP, Revillion F, Muller-Holzner E, Daxenbichler G, Marth C, Doppler W. Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 2007, 7:136. 10.1186/1471-2407-7-136, 1948006, 17651480.
58. Wang Y, Jiang H. Identification of a distal STAT5-binding DNA region that may mediate growth hormone regulation of insulin-like growth factor-I gene expression. J Biol Chem 2005, 280:10955-10963. 10.1074/jbc.M412808200, 15677453.
59. Dong J, Tong T, Reynado AM, Rosen JM, Huang S, Li Y. Genetic manipulation of individual somatic mammary cells in vivo reveals a master role of STAT5a in inducing alveolar fate commitment and lactogenesis in the absence of reproductive hormones. Dev Biol 2010, 346:196-203. 10.1016/j.ydbio.2010.07.027, 20691178.
60. Iavnilovitch E, Cardiff RD, Groner B, Barash I. Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 2004, 112:607-619. 10.1002/ijc.20484, 15382041.
61. Creamer BA, Sakamoto K, Schmidt JW, Triplett AA, Moriggl R, Wagner K-U. Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1. Mol Cell Biol 2010, 30:2957-2970. 10.1128/MCB.00851-09, 2876679, 20385773.
62. Santos SJ, Haslam SZ, Conrad SE. Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse. Endocrinology 2010, 151:2876-2885. 10.1210/en.2009-1282, 2875824, 20392833.
63. Srivastava S, Matsuda M, Hou Z, Bailey JP, Kitazawa R, Herbst MP, Horseman ND. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J Biol Chem 2003, 278:46171-46178. 10.1074/jbc.M308545200, 12952963.
64. Hosui A, Kimura A, Yamaji D, Zhu B-M, Na R, Hennighausen L. Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation. J Exp Med 2009, 206:819-831. 10.1084/jem.20080003, 2715112, 19332876.
65. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, Frank DA. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 2009, 7:966-976. 10.1158/1541-7786.MCR-08-0238, 19491198.
66. Vafaizadeh V, Klemmt P, Brendel C, Weber K, Doebele C, Britt K, Grez M, Fehse B, Desrivieres S, Groner B. Mammary epithelial reconstitution with genemodified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells 2010, 28:928-938.
67. Eilon T, Barash I. Different gene-expression profiles for the poorly differentiated carcinoma and the highly differentiated papillary adenocarcinoma in mammary glands support distinct metabolic pathways. BMC Cancer 2008, 8:270. 10.1186/1471-2407-8-270, 2564980, 18811984.
68. Nevalainen MT, Xie J, Bubendorf L, Wagner K-U, Rui H. Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol 2002, 16:1108-1124. 10.1210/me.16.5.1108, 11981045.
69. Oakes SR, Naylor MJ, Asselin-Labat M-L, Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard MA, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader JE, Ormandy CJ. The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev 2008, 22:581-586. 10.1101/gad.1614608, 2259028, 18316476.
70. Humphreys RC, Hennighausen L. Transforming growth factor alpha and mouse models of human breast cancer. Oncogene 2000, 19:1085-1091. 10.1038/sj.onc.1203278, 10713694.
71. Maroulakou IG, Oemler W, Naber SP, Klebba I, Kuperwasser C, Tsichlis PN. Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. J Cell Physiol 2008, 217:468-477. 10.1002/jcp.21518, 2871282, 18561256.
72. Ke Y, Lesperance J, Zhang EE, Bard-Chapeau EA, Oshima RG, Muller WJ, Feng G-S. Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation. J Biol Chem 2006, 281:34374-34380. 10.1074/jbc.M607325200, 1761121, 16959766.
73. Edwards GM, Wilford FH, Liu X, Hennighausen L, Djiane J, Streuli CH. Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. J Biol Chem 1998, 273:9495-9500. 10.1074/jbc.273.16.9495, 9545277.
74. Naylor MJ, Li N, Cheung J, Lowe ET, Lambert E, Marlow R, Wang P, Schatzmann F, Wintermantel T, Schuetz G, Clarke AR, Mueller U, Hynes NE, Streuli CH. Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol 2005, 171:717-728. 10.1083/jcb.200503144, 2171573, 16301336.
75. Leonoudakis D, Singh M, Mohajer R, Mohajer P, Fata JE, Campbell KP, Muschler JL. Dystroglycan controls signaling of multiple hormones through modulation of STAT5 activity. J Cell Sci 2010, 123:3683-3692. 10.1242/jcs.070680, 2964112, 20940259.
76. Wu W-J, Lee C-F, Hsin C-H, Du J-Y, Hsu T-C, Lin T-H, Yao T-Y, Huang C-H, Lee Y-J. TGF-beta inhibits prolactin-induced expression of beta-casein by a Smad3-dependent mechanism. J Cell Biochem 2008, 104:1647-1659. 10.1002/jcb.21734, 18335503.
77. Cocolakis E, Dai M, Drevet L, Ho J, Haines E, Ali S, Lebrun J-J. Smad signaling antagonizes STAT5-mediated gene transcription and mammary epithelial cell differentiation. J Biol Chem 2008, 283:1293-1307.
78. Wang Z, Li G, Tse W, Bunting KD. Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood 2009, 113:4856-4865. 10.1182/blood-2008-09-181107, 2686137, 19258595.
79. Liu F, Kunter G, Krem MM, Eades WC, Cain JA, Tomasson MH, Hennighausen L, Link DC. Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5. J Clin Invest 2008, 118:946-955. 2248325, 18292815.
80. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, Li D, Durum SK, Jiang Q, Bhandoola A, Hennighausen L, O'Shea JJ. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA 2006, 103:1000-1005. 10.1073/pnas.0507350103, 1327727, 16418296.
81. Liu S, Dontu G, Wicha M. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005, 7:86-95. 10.1186/bcr1021, 1143566, 15987436.
82. Ren S, Cai HR, Li M, Furth PA. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 2002, 21:4335-4339. 10.1038/sj.onc.1205484, 12082622.
83. Sakamoto K, Triplett AA, Schuler LA, Wagner KU. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. Oncogene 2010, 29:5359-5369. 10.1038/onc.2010.274, 2997721, 20639901.
84. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004, 22:2053-2060. 10.1200/JCO.2004.11.046, 15169792.
85. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 2004, 108:665-671. 10.1002/ijc.11619, 14696092.
86. Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 2006, 13:885-893. 10.1677/erc.1.01095, 16954437.
87. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H. Loss of nuclear localized and tyrosine phosphorylated stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 2011, 29:2448-2458. 10.1200/JCO.2010.30.3552, 21576635.
88. Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, Johnson KJ, Neilson LM, Liu C, Brill KL, Rosenberg AL, Witkiewicz AK, Rui H. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res 2010, 70:1711-1721. 10.1158/0008-5472.CAN-09-2314, 2822876, 20124477.
89. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P. Identification of a gainof-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci USA 2008, 105:14533-14538. 10.1073/pnas.0800685105, 2567233, 18779591.
90. Mohankumar KM, Perry JK, Kannan N, Kohno K, Gluckman PD, Emerald BS, Lobie PE. Transcriptional activation of signal transducer and activator of transcription (STAT) 3 and STAT5B partially mediate homeobox A1-stimulated oncogenic transformation of the immortalized human mammary epithelial cell. Endocrinology 2008, 149:2219-2229. 10.1210/en.2007-1320, 18276758.
91. Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, Lappin TRJ. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res 2010, 8:615-626. 10.1158/1541-7786.MCR-09-0264, 20353997.
92. Sultan AS, Brim H, Sherif ZA. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci 2008, 99:272-279. 10.1111/j.1349-7006.2007.00685.x, 18271926.
93. Gutzman JH, Rugowski DE, Nikolai SE, Schuler LA. Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context. Oncogene 2007, 26:6341-6348. 10.1038/sj.onc.1210454, 3190200, 17438530.
94. Barclay JL, Anderson ST, Waters MJ, Curlewis JD. SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer 2009, 124:1756-1766. 10.1002/ijc.24172, 19115200.
95. Yuan T, Wang Y, Zhao ZJ, Gu H. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J Biol Chem 2010, 285:14861-14870. 10.1074/jbc.M109.099879, 2865303, 20335174.
96. Perotti C, Liu R, Parusel CT, Bocher N, Schultz J, Bork P, Pfitzner E, Groner B, Shemanko CS. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res 2008, 10:R94. 10.1186/bcr2193, 2656886, 19014541.
97. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009, 220:292-296. 10.1002/jcp.21791, 2874239, 19415697.
98. Sarfstein R, Maor S, Reizner N, Abramovitch S, Werner H. Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol 2006, 252:241-246. 10.1016/j.mce.2006.03.018, 16647191.
99. Ciocca DR, Gago FE, Fanelli MA, Calderwood SK. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: clinical implications. J Steroid Biochem Mol Biol 2006, 102:32-40. 10.1016/j.jsbmb.2006.09.008, 17049840.